

Sources of Information

Bevacizumab

Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. *Ophthalmology*. 2006 Mar;113(3):363-372.

Chan WM, Lai TY, Liu DT, et al. Intravitreal bevacizumab for myopic choroidal neovascularization: Six-month results of a prospective pilot study. *Ophthalmology*. 2007;114(12):2190-2196.

Iliev ME, Domig D, Wolfe-Schnurrbursch U, et al. Intravitreal bevacizumab in the treatment of neovascular glaucoma. *Am J Ophthalmol*. 2006;142(6):1054-1056.

Spaide RF, Laud K, Fine HF, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. *Retina*. 2006;26(4):383-90.

Yamamoto I, Rogers AH, Reichel E, et al. Intravitreal bevacizumab as treatment for subfoveal choroidal neovascularisation secondary to pathological myopia. *Br J Ophthalmol*. 2007;91:157-160.

Sources added based on a reconsideration request:

Aghajanian C, Sill MW, Darcy KM, et al. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. *Journal of Clinical Oncology*. 2011;29(16):2259-2265.

Alvarez EA, Brady WE, Walker JL, et al. Phase II trial of bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. *Gynecol Oncol*. (2013), <http://dx.doi.org/10.1016/j.ygyno.2012/12.022>.

Reinhardt J, Schott S, Mayer C, Sohn C, Eichbaum M. Long-term remission of an advanced recurrent endometrial cancer in a heavily pretreated patient using a combined regimen with bevacizumab and metronomic cyclophosphamide. *Anti-Cancer Drugs*. 2011;22(8):822-824.

Wright JD, Powell MA, Rader JS, Mutch DG, Gibb RK. Bevacizumab therapy in patients with recurrent uterine neoplasms. *Anticancer Research*. 2007;27:3525-3528.

Sources added based on a reconsideration request:

Best SR, Friedman AD, Landau-Zemer T, et al. Safety and dosing of bevacizumab (Avastin) for the treatment of recurrent respiratory papillomatosis. *Annals of Otolaryngology, Rhinology & Laryngology*. 2012;121(9):587-593.

Hawasli AH, Rubin JB, Tran DD, et al. Antiangiogenic agents for nonmalignant brain tumors. *J Neurol Surg B Skull Base*. June 2013;74(3):136-141.

Puchner MJ, Hans VH, Harati A, Lohmann F, Glass M, Herrlinger U. Bevacizumab-induced regression of anaplastic meningioma. *Annals of Oncology*. December 2010;12(12):2445-2446. doi: 10.1093/annonc/mdq634. Epub 2010 Nov 1.

Lou E, Sumrall AL, Turner S, et al. Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series. *J Neurooncol*. 2012 Aug;109(1):63-70. doi: 10.1007/s11060-012-0861-0. Epub 2012 Apr 26.

Zeitels SM, Barbu AM, Landau-Zemer T et al. Local injection of bevacizumab (Avastin) and angiolytic KTP laser treatment of recurrent respiratory papillomatosis of the vocal folds: a prospective study. *Annals of Otolaryngology, Rhinology & Laryngology*. 2011;120(10):627-634.

Zeitels SM, Lopez-Guerra G, Burns JA, Lutch M, Friedman AM, Hillman RE. Microlaryngoscopic and office-based injection of bevacizumab (Avastin) to enhance 532-nm pulsed KTP laser treatment of glottal papillomatosis. *Annals of Otolaryngology, Rhinology & Laryngology*. 2009;118(9)Suppl 201:1-24.

Sources added for symptomatic post-radiation necrosis of the central nervous system:

Levin VA, Bidaut L, Hou P, et al. Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the CNS. *Int J Radiat Oncol Biol Phys*. 2011 April 1;79(5):1487-1495.

Boothe D, Young R, Yamada Y, Prager A, Chan T, Beal K. Bevacizumab as a treatment for radiation necrosis of brain metastases post stereotactic radiosurgery. *Neuro-Oncology*. 2013 Sep;15(9):1257-1263.

Bortezomib

Moreau P, Pylypenko H, Grosicki S, et, al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. *Lancet Oncol*. 2011;12:431-440.

The following sources were added as a result of a reconsideration request received November 21, 2012:

Everly MJ. An update on antibody reduction and rejection reversal following bortezomib use: a report of 54 cases across 10 centers. *Clin Transpl*. 2010;33:353-362.

Walsh RC, Alloway RR, Girnita AL, Woodle ES. Proteasome inhibitor-based therapy for antibody-mediated rejection. *Kidney International*. 2012;81:1067-1074.

The following sources were added as a result of a reconsideration request received on April 28, 2016:

De Sousa-Amorim E, Revuelta I, Diekmann F et al. Bortezomib for refractory acute antibody-mediated rejection in kidney transplant recipients. A single-center case series. *Nephrology (Carlton)*. 2015 Oct 22.

Everly, MJ, Everly JJ, Susskind B et al. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. *Transplantation*. 2008 Dec 27;86:1754-1761.

Lee J, Kim BS Park Y, et al. The effect of Bortezomib on Antibody-Medicated Rejection after Kidney Transplantation. *Yonsei Med J*. 2015 Nov;56(6):1638-1642.

Nigos JG, Arora S, Nath P, et al. Treatment of antibody-mediated rejection in kidney transplant recipients: a single-center experience with bortezomib-based regimen. *Exp Clin Transplant*. 2012 Dec;10(6): 609-613.

Roberts DM, Jiang SH, Chadban SJ. The treatment of acute antibody-mediated rejection in kidney transplant recipients-a systematic review. *Transplantation*. 2012 Oct 27; 94(8):775-783.

Sadaka B, Alloway RR, Shields AR, Schmidt NM, Woodle ES. Proteasome inhibition for antibody mediated allograft rejection. *Semin Hematol*. 2012 Jul;49(3):263-269.

Waiser J, Budde K, Schutz M, et al. Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejection. *Nephrol Dial Transplant*. 2012 Mar;27(3):1246-1251.

Walsh RC, Everly JJ, Brailey P, et al. Proteasome inhibitor based primary therapy for antibody-mediated renal allograft rejection. *Transplantation*. 2010 Feb;89:277-284.

Denosumab (Prolia™, Xgeva™)

Based on a reconsideration request the following sources have been added:

Ellis GK, Bone HG, Chlebowski R, et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. *J Clin Oncol*. 2008;26(30):4875-4882.

FDA label for Prolia® (denosumab) revised 05/18/2018.

Smith MR, Egerdie B, Toriz NH, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. *N Engl J Med*. 2009;361:745-755.

Eculizumab (Soliris®)

Peer Reviewed Literature:

Brodsky RA, Young NS, Antonioli E, et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. *Blood*. 2008;111(4):1840-1847.

Hill A, Hillmen P, Richards SJ, et al. Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria. *Blood*. 2005;106(7):2559-2565.

Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. *N Engl J Med*. 2006;355(12):1233-1243.

Kelly RJ, Hill A, Arnold LM, et al. Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. *Blood*. 2011;117(25): 6786-6792.

Lee JW, Jang JH, Kim JS, et al. Clinical signs and symptoms associated with increased risk for thrombosis in patients with paroxysmal nocturnal hemoglobinuria from a Korean Registry. *Int J Hematol*. 2013;97(6):749-757.

Schrezenmeier H, Muus P, Socié G, et al. Baseline characteristics and disease burden in patients in the International Paroxysmal Nocturnal Hemoglobinuria Registry. *Haematologica*. 2014;99(5):922-929

Braun MC, Stablein DM, Hamiwka LA, Bell L, Bartosh SM, Strife CF. Recurrence of membranoproliferative glomerulonephritis Type II in renal allografts: the North American Pediatric Renal Transplant Cooperative Study Experience. *J Am Soc Nephrol*. 2005;16:2225-2233.

Smith RJH, Alexander J, Barlow PN, et al. New approaches to the treatment of dense deposit disease. *J Am Soc Nephrol*. 2007;18:2447-2456.

McCaughan JA, O'Rourke DM, Courtney AE. Recurrent dense deposit disease after renal transplantation: an emerging role for complementary therapies. *American Journal of Transplantation*. 2012;12:1046-1051.

Bomback AS, Smith RJ, Barite GR, et al. Eculizumab for dense deposit disease and C3 glomerulonephritis. *Clin J Am Soc Nephrol*. 2012;7:748-756.

Daina E, Noris M, Remuzzi G. Eculizumab in a patient with dense deposit disease. *N Engl J Med*. 2012;336(15):1161-1163.

Vivarelli M, Pasini A, di Bologna AO. Eculizumab for the treatment of dense-deposit disease. *N Engl J Med*. 2012;336(12):1163-1164.

Radhakrishnan S, Lunn A, Kirschfink M, et al. Eculizumab and refractory membranoproliferative glomerulonephritis. *Engl J Med*. 2012;336(12):1165-1166.

Herlitz LC, Bomback AS, Markowitz GS, et al. Pathology after eculizumab in dense deposit disease and C3 GN. *J Am Soc Nephrol*. 2012;23:1229-1237.

Ozkaya O, Nalcacioglu H, Tekcan D, et al. Eculizumab therapy in a patient with dense-deposit disease associated with partial lipodystrophy. *Pediatr Nephrol*. 2014;29:1283-1287.

Sánchez-Moreno A, De la Cerda F, Cabrera R, et al. Eculizumab in dense-deposit disease after renal transplantation. *Pediatr Nephrol*. 2014;29:2055-2059.

Oosterveld MJS, Garrelfs MR, Hoppe B, et al. Eculizumab in pediatric dense deposit disease. *Clin J Am Soc Nephrol*. 2015;10:1773-1782.

Le Quintrec M, Lionet A, Kandel C, et al. Eculizumab for treatment of rapidly progressive C3 glomerulopathy. *Am J Kidney Dis*. 2015;65(3):484-489.

Payette A, Patey N, Dragon-Durey MA, Frémeaux-Bacchi V, Le Deist F, Lapeyraque AL. A case of C3 glomerulonephritis successfully treated with Eculizumab. *Pediatr Nephrol*. 2015;30(6):1033-1037.

Kopel T, Salant DJ. C3 glomerulopathies: Dense deposit disease and C3 glomerulonephritis. <http://www.uptodate.com/contents/c3-glomerulopathies-dense-deposit-disease-and-c3-glomerulonephritis>. Accessed 11/13/2017.

Filgrastim, Pegfilgrastim, Tbo-filgrastim and biosimilars

Empire Medicare Services carrier LCD NY [L7515]

The following sources were added as a result of a reconsideration request received on March 28, 2012:

Aapro MS, Cameron DA, Pettengell R, et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. *European Journal of Cancer*. 2006;42:2433-2453.

Brusamolino E, Rusconi C, Montalbetti L, et al. Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphomas: a phase II study of feasibility and toxicity. *Haematologica*. 2006;91:496-502.

Burstein HJ, Parker LM, Keshaviah A, et al. Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy. *Journal of Clinical Oncology*. 2005;23(33):8340-8347.

Engery A, Doehner H, Ho AD, et al. Pegfilgrastim supports delivery of BEACOPP chemotherapy administered every 14 days. *The Journal of Supportive Oncology*. 2005;3(2)supplement 1:48-49.

Hecht JR, Pillai M, Gollard R, et al. A randomized, placebo-controlled phase II study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy. *Clinical Colorectal Cancer*. 2010;9(2):95-101.

Lopez A, de Sevilla AF, Castaigne S, et al. Pegfilgrastim supports delivery of CHOP-R chemotherapy administered every 14 days: a randomized phase II study. *The Journal Of Supportive Oncology*. 2005;3(2)supplement 1:46-47.

Mey UJM, Maier A, Schmidt-Wolf IGH, et al. Pegfilgrastim as hematopoietic support for dose-dense chemoimmunotherapy with R-CHOP-14 as first line therapy in elderly patients with diffuse large B cell lymphoma. *Support Care Cancer*. 2007;15:877-884.

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™). Myeloid Growth Factors. Version 1.2011. NCCN.org.

Piedbois P, Serin D, Priou F, et al. Dose-dense adjuvant chemotherapy in node-positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study. *Anal of Oncology*. 2007;18:52-57.

Pirker R, Ulsperger E, Messner J, et al. Achieving full-dose, on-schedule administration of ACE chemotherapy every 14 days for the treatment of patients with extensive small-cell lung cancer. *Lung*. 2006;184:279-285.

Yang B-B, Hill RL, Hollifield AM, et al. Pegfilgrastim serum concentrations on the twelfth day after dosing are unlikely to stimulate granulopoiesis: a retrospective analysis of six clinical trials in a variety of cancer populations. *The Journal Of Supportive Oncology*. 2004;2(2):48-49.

Younes A, Fayad L, Romaguera J, Pro B, Goy A, Wang M. Safety and efficacy of once-per-cycle pegfilgrastim in support of ABVD chemotherapy in patients with Hodgkin lymphoma. *European Journal of Cancer*. 2006;42:2976-2981.

Hyaluronans Intra-articular Injections

AdminaStar Federal carrier LCD Indiana [L7500] Kentucky [L7493].

Intra-articular hyaluronan injections for osteoarthritis of the knee: issues for coverage policy and utilization. *JMCM*. 2008;11(2)(suppl).

Lussier A, Cividino AA, McFarlane CA, Olszynski WP, Potashner WJ, De Medicis R. Viscosupplementation with hylan for the treatment of osteoarthritis: findings from clinical practice in Canada. *J Rheumatol*. 1996;23(9):1579-1589.

Raynaud JP, Goldsmith CH, Bellamy N, et al. Effectiveness and safety of repeat courses of hylan G-F 20 in patients with knee osteoarthritis. *Osteoarthritis Cartilage*. 2005;13(2):111-119.

Scale D, Wobig M, Wolpert W. Viscosupplementation of osteoarthritic knees with hylan: a treatment schedule study. *Current Therapeutic Research*. 1994;3(55):220-232.

Scali, JJ. Intra-articular hyaluronic acid in the treatment of osteoarthritis of the knee: a long term study. *European Journal of Rheumatology and Inflammation*. 1995;1(15):57-62.

Ueno Y, Kuramoto K, Konno N, et al. Investigation on result of use after launch of ARTZ and ARTZ Dispo - evaluation on the efficacy, safety and utility in the medication for osteoarthritis of the knee and peri-arthritis of the shoulder. *Jpn Pharmacol Ther*. 1995;23(8):2151-2170.

Viscosupplementation: a treatment for osteoarthritis. *The Journal of Rheumatology*. 1993;39(20).

Waddell DD, Bricker DC. Hylan G-F 20 tolerability with repeat treatment in a large orthopedic practice: a retrospective review. *J Surg Orthop Adv*. 2006;15(1):53-59.

Waddell DD, Kolomytkin OV, Dunn S, Marino AA. Hyaluronon suppresses IL-1-induced metalloproteinase activity from synovial tissue. *Clin Orthop Relat Res*. 2007;465:241-248

Ibandronate Sodium (e.g., Boniva®)

Qaseem A, Snow V, Shekelle P, et al. Pharmacologic treatment of low bone density or osteoporosis to prevent fractures: A clinical practice guideline from the American College of Physicians. *Ann Intern Med*. 2008;149:404-415.

Ringe JD, Faber H, Farahmand P, Dorst A. Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study. *Rheumatol Int*. 2006;26:427-431.

The following references have been added based on a reconsideration request received April 20, 2012

Amital H, Applbaum YH, Vasilliev L, Rubinow A. Hypertrophic pulmonary osteoarthropathy: control of pain and symptoms with pamidronate. *Clin Rheumatol*. 2004;23:230-332.

Jayakar BA, Abelson AG, Yao Q. Treatment of hypertrophic osteoarthropathy with zoledronic acid: case report and review of the literature. *Semin Arthritis Rheum*. 2011;41(2):291-296.

Martinez-Lavin M, Vargas A, Rivera-Vinãs M. Hypertrophic osteoarthropathy: a palindrome with a pathogenic connotation. *Current Opinion Rheumatol*. 2008;20(1):88-91.

Yao Q, Altman RD, Brahn E. Periostitis and hypertrophic pulmonary osteoarthropathy: report of 2 cases and review of literature. *Semin Arthritis Rheum*. 2009;38(6):458-466.

Infliximab, Infliximab-dyyb, Infliximab-abda (e.g., Remicade™, Inflectra™, Renflexis)

Baughman RP, Lower EE. Infliximab for Refractory Sarcoidosis. *Sarcoidosis Vasculitis and Diffuse Lung Diseases*. 2001;18:70-74.

Doty JD. Treatment of Sarcoidosis with Infliximab. *Chest*. 2005;127(3):1064-71.

Estrach C, Mpofo S, Moots RJ. Behcet's Syndrome: response to infliximab after failure of etanercept. *Rheumat*. 2002;41(10):1213-14.

Keino O, Okada AA, Watanabe T, et al. Decreased ocular inflammatory attacks and background retinal and disc vascular leakage in patients with Behcet's disease on infliximab therapy. *Br J Ophthalmol*. 2001;95(9):1245-50. doi:10.1136/bjo.2010.194464.

Keystone, EC. The Utility of Tumour Necrosis Factor In Blockade in Orphan Diseases. *Annals of the Rheumatic Diseases*. 2004;63:ii79-ii83.

Scott D, Roberts SD, Wilkes DS, Burgett RA, Knox KS. Refractory Sarcoidosis Responding to Infliximab. *Chest*. 2003;124:2028-2031.

Hoffman GS, Merkel PA, Brasington RD, Lenschow DJ, Liang P. Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. *Arthritis Rheum*. 2004;50(7):2296-2304.

Karageorgaki ZT, Marvragani CP, Papathanasiou MA, Skopouli FN. Infliximab in Takayasu arteritis: a safe alternative? *Clinical Rheumatol*. 2007;26(6):984-987.

Patriarca F, Sperotto A, Damiani D, et al. Infliximab treatment for steroid-refractory acute graft-versus-host disease. *Haematologica*. 2004 Nov;89(11):1352-1359.

Sleight BS, Chan KW, Braun TM, Serrano A, Gillman AL. Infliximab for GVHD therapy in children. *Bone Marrow Transplantation*. 2007;40:473-480.

Ward MM, Deodhar A, Akl EA, et al. American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. *Arthritis Rheumatol*. 2016 Feb;68(2):282-298. doi: 10.1002/art.39298. Epub 2015 Sep 24.

Johnston RL, Lutzky J, Chodhry A, Barkin JS. Cytotoxic T-lymphocyte-associated antigen 4 antibody-induced colitis and its management with infliximab. *Dig Dis Sci*. 2009;54(11):2538-2540.

Klair JS, Girotra M, Hutchins LF, Caradine KD, Aduli F, Garcia-Saenz-de-Sicilia M. Ipilimumab-Induced Gastrointestinal Toxicities: A Management Algorithm. *Dig Dis Sci*. 2016;61(7):2132-2139.

Linardou H, Gogas H. Toxicity management of immunotherapy for patients with metastatic melanoma. *Ann Transl Med*. 2016;4(14):272.

Pages C, Gornet JM, Monsel G, et al. Ipilimumab-induced acute severe colitis treated by infliximab. *Melanoma Res*. 2013;23(3):227-230.

Villadolid J, Amin A. Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities. *Transl Lung Cancer Res*. 2015;4(5):560-575.

Merrill SP, Reynolds P, Kalra A, Biehl J, Vandivier RW, Mueller SW. Early administration of infliximab for severe ipilimumab-related diarrhea in a critically ill patient. *Ann Pharmacother*. 2014;48(6):806-810.

Minor DR, Chin K, Kashani-Sabet M. Infliximab in the treatment of anti-CTLA4 antibody (ipilimumab) induced immune-related colitis. *Cancer Biother Radiopharm*. 2009;24(3):321-325.

Toxicities associated with checkpoint inhibitor immunotherapy - UpToDate

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Melanoma Version 1, 2017 – November 10, 2016. accessed on line at: <https://www.nccn.org/>

Intravenous Immune Globulin (IVIG)

CMS Publication 100-03, *Medicare National Coverage Decisions Manual*, Chapter 1, Section 250.3

Greenberg S. Proposed immunologic models of the inflammatory myopathies and potential therapeutic implications. *Neurology*.2007;69:2008-2019.

Griggs R. The current status of treatment for inclusion-body myositis. *Neurology*.2006;66(suppl 1):S30-S32.

Heckenlively JR, Ferreyera HA. Autoimmune retinopathy: A review and summary. *Semin Immunopathol*. 2008;30:127-134.

Koski C, Patterson J. Intravenous immunoglobulin use for neurologic diseases. *Journal of Infusion Nursing*.2006;29:521-526.

Kurz D, Egan RA, Rosenbaum JT. Treatment of corticosteroid dependent optic neuropathy with intravenous immunoglobulin.*AM J Ophthalmol*.2005;140(6):1132-1133.

Other Medicare contractor policies:

Empire Medicare Services carrier LCD (New Jersey [L3666], New York [L3097])

Anthem East Health Plans fiscal intermediary LCD New Hampshire/Vermont [L658]

Associated Hospital Services fiscal intermediary LCD Maine/ Massachusetts [L445]

NHIC, Corp. LCD Intravenous Immunoglobulin (IVIG) [L3147]

Wisconsin Physicians Service Insurance Corporation LCD Immune Globulins [L30147]

Stiebel-Kalish H, Hammel V, van Everdingen J, Hana-Baron R, Lee AG. Intravenous immunoglobulin in recurrent-relapsing inflammatory optic neuropathy. *Can J Ophthalmol*.2010;45(1):71-75.

U.S. Food and Drug Administration label accessed on line at <http://www.accessdata.fda.gov/scripts/cder/drugsatfda/> on 07/11/2007.

Based on a reconsideration request, the following sources have been added:

European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of paraproteinemic demyelinating neuropathies. Report of a Joint Task Force of the European Federation of Neurological Societies and the Peripheral Nerve Society first revision. *J Peripher Nerv Syst*.2010 Sep;15(3):185-95. doi: 10.1111/j.1529-8027.2010.00278.x.

Koski CL, Baumgarten M, Magder LS, et al. Derivation and validation of diagnostic criteria for chronic inflammatory demyelinating polyneuropathy. *J Neurol Sci*. 2009 Feb 15;277(1-2):1-8,doi:10.1016/j.jns.2008.11.015.

Based on a reconsideration request, the following sources have been added:

Crabot Y, Terrier B, Rozenberg F, et al. Intravenous immunoglobulin therapy for pure red cell aplasia related to human parvovirus B19 infection: a retrospective study of 10 patients and review of the literature. *Clin Infect Dis*. 2013 Apr;56:968-977.

Sawada K, Fujishima N, Hirokawa M. Acquired pure red cell aplasia: updated review of treatment. *British Journal of Haematology*. 2008 Aug;142(4):505-514.

Luteinizing Hormone-Releasing Hormone (LHRH) Analogs

Agency for Health Care Policy and Research (AHCPR). Evidence Report/Technology Assessment: Number 4. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostatic cancer. Available at: <http://www.ahrq.gov/clinic/epcsums/prosumm.htm>. Accessed November 30, 2005.

ACCC Drug Bulletin, vol. 14, no. 1 (February 2005).

Association of Community Cancer Center (ACCC) *Compendia-Based Drug Bulletin*. Vol. 15, No. 1. February 2006. Also available at: http://www.accc-cancer.org/PUBS/drugbul_feb06.pdf. Accessed March 6, 2006.

DiBiase ST, Roach M. Radiation therapy for localized prostate cancer. ©2005 UpToDate®. Accessed at <https://store.uptodate.com/app/index.asp> 10/31/2005.

Drug Facts and Comparisons, St. Louis, 1996.

Hornstein MD, Surrey ES, Weisberg GW, Casino LA. Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study. *Obstetrics and Gynecology*. 1998;91(1):16-24.

Ling, FW. Randomized controlled trial of depot leuprolide in Patients with chronic pelvic pain and clinically suspected endometriosis. Pelvic Pain Study Group. *Obstetrics and Gynecology*. 1999;93(1):51-58.

Moghissi KS, Schlaff WD, Olive DL, Skinner MA, Yin H. Goserelin acetate (Zoladex) with or without hormone replacement therapy for the treatment of endometriosis. *Fertility and Sterility*. 1998;69(6):1056-1062.

Ogden JE, Muniz A, et. al. Department of Veterans Affairs Pharmacy Benefit Management Strategic Health Group, LHRH Agonist Drug Class Review. Washington D.C., Published in or after 1996, at www.dppm.med.va.gov/newsite/revlhrh.html.

Relative Effectiveness and Cost-Effectiveness of Methods of Androgen Suppression in the Treatment of Advanced Prostatic Cancer. *Evidence Report/Technology Assessment: Number 4*. <http://www.ahcpr.gov/clinic/prosumm.htm>.

Seidenfeld J, Samson DJ, Hasselblad V, et. al. Single-therapy androgen suppression in men with advanced prostate cancer: A systematic review and meta-analysis. *Ann Intern Med*. 2000;132:566-577.

Taylor, CW, Green S, Dalton WS, et al. Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study. *Journal of Clinical Oncology*. 1998;16(3):994-999.

Triptorelin Pamoate (Trelstar). *The Medical Letter on Drugs and Therapeutics*. 2002;4(1132):51-52.

Vercellini P, Crosignani PG, Fadini R, Radici E, Belloni C, Sismondi P. A gonadotropin-releasing hormone agonist compared with expectant management after conservative surgery for symptomatic endometriosis. *British Journal of Obstetrics and Gynecology*. 1999;106(7):672-677.

The following source was added as a result of a reconsideration request received May 10, 2016:

Management of Endometriosis. Practice Bulletin. *The American College of Obstetricians and Gynecologists*. Vol. 116, No. 1, July 2010. 223-236.

Paclitaxel (e.g., Taxol®/Abraxane™)

Akram T, Maseelall P, Fanning J. Carboplatin and paclitaxel for the treatment of advanced or recurrent endometrial cancer. *Am Jnl Obstetrics and Gynecology*. 2005;192:1365.

Hoskins PJ, Swenerton KD, Pike JA, et al. Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: A phase II Study. *J Clin Oncol*. 2001;19(20):4048-4053.

Price FV, Edwards RP, Kelley JL, Kunschner AJ, Hart LA. A Trial of outpatient paclitaxel and carboplatin for advanced, recurrent, and histologic high-risk endometrial carcinoma: Preliminary Report. *Semin Oncol*. 1997;24(5 Suppl 15):S15-78-S15-82.

Walker L, Schalch H, King DM, et al. Phase II trial of weekly paclitaxel in patients with advanced melanoma. *Melanoma Res*. 2005;15(5):453-459.

Rituximab (Rituxan®), Rituximab and hyaluronidase human (Rituxan Hycela™) and Rituximab-abbs (Truxima®)

Cree S, Lamb K, Morgan A, Chen E, Waubant, Genain C. An open label study of the effects of rituximab in neuromyelitis optica. *Neurology*. 2005;64:1270-1272.

Tyde G, Genberg H, Tollemar J, et al. A randomized, doubleblind, placebo-controlled, study of single-dose rituximab as induction in renal transplantation. *Transplantation*. 2009;87:1325-1329.

Vo AA, Lukovsky M, Toyoda M, et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. *N Engl J Med*. 2008;359(3):242-251.

Vo AA, Peng A, Toyoda M, et al. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation. *Transplantation*. 2010;89(9):1095-1102.

Based on a reconsideration the following sources have been added:

Chung L, Genovese MC, Fiorentino DF. A pilot trial of rituximab in the treatment of patients with dermatomyositis. *Arch Dermatol*. 2007;143:763-767.

Levine TD. Rituximab in the treatment of dermatomyositis. An open-label pilot study. *Arthritis & Rheumatism*. 2005;2(52):601–607.

Mok CC, Ho Ly, To CH. Rituximab for refractory polymyositis: An open-label prospective study. *J Rheumatol*. 2007;34:1864–1868.

Noss EH, Hausner-Sypek DL, Weinblatt ME. Rituximab as therapy for refractory polymyositis and dermatomyositis. *J Rheumatol*. 2006;33:1021-1026.

Khanna D, Chong KKL, Affyan NF, et al. Rituximab treatment of patients with severe, corticosteroid-resistant thyroid-associated ophthalmopathy. *Ophthalmology*. 2010;117(1):133-139.e2.

Salvi M, Vannucchi G, Campi I, et al. Treatment of Graves' disease and associated ophthalmopathy with the anti-CM20 monoclonal antibody rituximab: an open study. *European Journal of Endocrinology*. 2007;156:33-40.

The following sources were added as a result of a reconsideration request received July 24, 2012:

Irani SR, Michell AW, Lang B, et al. Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. *Ann Neurol*. 2011;69:892-900.

Vernino S, Geschwind M, Boeve B. Autoimmune encephalopathies. *The Neurologist*. 2007;13:140-147.

The following sources were added as a result of a reconsideration request received December 26, 2012:

Munch C, Anagnostou P, Meyer R, Haas J. Rituximab I chronic inflammatory demyelinating polyneuropathy associated with diabetes mellitus. *Journal of the Neurological Sciences*. 2007;256:100-102.

Benedetti L, Briani C, Franciotta D, et al. Rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a report of 13 cases and review of the literature. *J Neural Neurosurg Psychiatry*. 2011;82:306-308.doi:10.1136/mnp.2009.188912.

Cocilo D, Grimaldi S, Paolasso I, et al. Immunosuppressive treatment in refractory chronic inflammatory

demyelinating polyradiculoneuropathy. A nationwide retrospective analysis. *European Journal of Neurology*. 2011;10:1417-1421.

Briani C, Zara G, Zambello R, Trentin L, Rana M, Zaja F. Rituximab-responsive CIDP. *European Journal of Neurology*. 2004;11:788-791.

Knecht H, Baumberger M, Tobón A, Steck A. Sustained remission of CIDP associated with Evans syndrome. *Neurology*. 2004;63(4):730-732.

Pestronk A, Florence J, Miller T, Choksi R, Al-Lozi MT, Levine TD. Treatment of IgM antibody associated polyneuropathies using rituximab. *J Neurol Neurosurg Psychiatry*. 2003;74(4):485-489.

Levine TD, Pestronk A. IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using rituximab. *Neurology*. 1999;52(8):1701-1704.

Based on a reconsideration request the following sources have been added:

Díaz-Manera J, Martínez-Hernández, E, Querol L, et al. Long-lasting treatment effect of rituximab in MuSK myasthenia. *Neurology*. 2012 Jan 17;78(3):189-193. doi:10.1212/WNL.0b013e3182407982. Epub 2012 Jan 4.

Lebrun C, Bourg V, Tieulie N, Thomas P. Successful treatment of refractory generalized myasthenia gravis with rituximab. *European Journal of Neurology*. 2009 Feb;16(2):246-250. doi:10.1111/j.1468-1331.2008.02399.x.

Zebardast N, Patwa HS, Novella SP, Goldstein JM. Rituximab in the management of refractory myasthenia gravis. *Muscle Nerve*. 2010 Mar;41(3):375-378. doi:10.1002/mus.21521.

Based on a reconsideration request the following sources have been added:

De Vita S, Quartuccio L, Isola M, et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. *Arthritis Rheum*. 2012 Mar;64(3):843-853. doi: 10.1002/art.34331.

Fervenza FC, Leise MD, Roccatello D, Kyle RA. Treatment of the mixed cryoglobulinemia syndrome. www.uptodate.com. ©2013 UpToDate®

Gottenberg JE, Cinquetti G, Larroche C, et al. Efficacy of rituximab in systemic manifestations of primary Sjögren's syndrome: results on 78 patients of the Autoimmune and Rituximab registry. *Ann Rheum Dis*. 2013;72:1026-1031. doi: 10.1136/annrheumdis-2012-202293.

Meijer JM, Meiners PM, Vissink A, et al. Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial. *Arthritis Rheum*. 2010 Apr;62(4):960-968. doi: 10.1002/art.27314.

Mekinian A, Ravaud P, Hatron PY, et al. Efficacy of rituximab in primary Sjögren's syndrome with peripheral nervous system involvement: results from the AIR registry. *Ann Rheum Dis*. 2012;71:84-87. doi: 10.1136/annrheumdis-2011-200086.

Sneller MC, Hu Z, Langford CA. A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis. *Arthritis Rheum*. 2012 Mar;64(3):835-842. doi: 10.1002/art.34322.

Terrier B, Launay D, Kaplanski G, et al. Safety and efficacy of rituximab in nonviral cryoglobulinemia vasculitis: data from the French Autoimmunity and Rituximab registry. *Arthritis Care Res (Hoboken)*. 2010 Dec;62(12):1787-1795. doi: 10.102/acr.20318.

Based on a reconsideration request the following sources have been added:

Busch M, Ruster C, Schinköthe C, Gerth J, Wolf G. Rituximab for the second- and third-line therapy of idiopathic membranous nephropathy: a prospective single center study using a new treatment strategy. *Clin Nephrol*. 2013 Aug;80(2):105-113. doi: 10.5414/CN107912.

Cravedi P, Ruggenti P, Sghirlanzoni MC, Remuzzi G. Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy. *Clin J Am Soc Nephrol*. 2007 Sep;2(5):932-937.

Cravedi P, Sghirlanzoni MC, Marasá M, Salerno A, Remuzzi G, Ruggenti P. Efficacy and safety of rituximab second-line therapy for membranous nephropathy: a prospective, matched-cohort study. *Am J Nephrol*. 2011;33(5):461-468. doi: 10.1159/000327611.

Fervenza FC, Abraham RS, Erickson SB, et al. Rituximab therapy in idiopathic membranous nephropathy: a 2-year study. *Clin J Am Soc Nephrol*. 2010 Dec;5(12):2188-2198. doi: 10.2215/CJN.05080610.

Fervenza FC, Gosio FG, Erickson SB, et al. Rituximab treatment of idiopathic membranous nephropathy. *Kidney Int*. 2008 Jan;73(1):117-25.

Kattah AG, Fervenza FC, Roccatello D. Rituximab-based novel strategies for the treatment of immune-mediated glomerular diseases. *Autoimmunity Reviews*. 2013 Jun;12(8):854-9. doi: 10.1016/j.autrev.2012.09.002.

Remuzzi G, Chiurciu C, Abbate M, Brusegan V, Bontempelli M, Ruggenti P. Rituximab for idiopathic membranous nephropathy. *Lancet*. 2002 Sep 21;360(9337):923-924.

Ruggenti P, Cravedi P, Chianca A, et al. Rituximab in idiopathic membranous nephropathy. *J Am Soc Nephrol*. 2012 Aug;23(8):1416-1425. doi: 10.1681/ASN.2012020181.

Ruggenenti P, Ruggiero B, Cravedi P, et al. Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome. *J Am Soc Nephrol*. 2014 Apr;25(4):850–863. doi: 10.1681/ASN.2013030251.

Based on a reconsideration request the following sources have been added:

Kilidireas C, Anagnostopoulos A, Karandreas N, Mouselimi L, Dimopoulos MA. Rituximab therapy in monoclonal IgM-related neuropathies. *Leukemia & Lymphoma*. 2006 May;47(5):859-864.

Léger JM, Viala K, Nicolas G, et. al. Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy. *Neurology*. 2013;80:2217-2225.

Lunn MP, Nobile-Orazio E. Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies. *Cochrane Database Syst Rev*. May 16;5:CD002827. doi: 10.1002/14651858.CD002827.pub3.

Pestronk A, Florence J, Miller T, Choski R, Al-Lozi MT, Levine D. Treatment of IgM antibody associated polyneuropathies using rituximab. *J Neurol Neurosurg Psychiatry*. 2003;74:485-489.

Based on a reconsideration request the following sources have been added:

Cravedi P, Remuzzi G, Ruggenenti P. Rituximab in primary membranous nephropathy: first-line therapy, why not? *Nephron Clin Pract*. 2014;128:261-269.

Ruggenenti P, Debiec H, Ruggiero B, et al. Anti-phospholipase A₂ receptor antibody titer predicts post-rituximab outcome of membranous nephropathy. *J Am Soc Nephrol*. 2015;26:2545-2558.